The newest BTK inhibitor on the market, Eli Lilly’s Jaypirca, has s | In a phase 3 trial, the newest Bruton’s tyrosine kinase ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

After a first half that saw Publicis Groupe snap up six companies around the world, the advertising giant is continuing its ...

At long last, the Trump administration’s much-ballyhooed tariffs on pharmaceutical imports are materializing in a trade deal ...

Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO.

AbbVie, Gilead Sciences and GSK marked World Hepatitis Day on Monday, outlining the need to tackle the stigma and discrimination associated with the group of viruses to eliminate them as a public ...

Once touted as a potential powerhouse treatment for a variety of inflammatory conditions, Galapagos’ JAK inhibitor Jyseleca ...

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Monday, the FDA said Sarepta may resume treating ambulatory DMD patients with Elevidys. The recommendation comes just 10 days ...

The injectable production specialist has snapped up a 65-acre property with more than 300,000 square feet of usable space to ...

The importance of a homegrown biomanufacturing workforce to North Carolina’s swiftly growing life sciences industry was a consistent theme during a recent press tour of the state attended by Fierce | ...